Skip to content
- Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
- Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
- Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
- Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic.
- Mattiolo P, Kryklyva V, Brosens LA, Mafficini A, Lawlor RT, Milella M, Scarpa A, Corbo V, Luchini C.
- Expert Opin Ther Targets. 2021 Dec 22. doi: 10.1080/14728222.2022.2021397. Epub ahead of print.
- Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
- Philp L, Alimena S, Ferris W, Saini A, Bregar AJ, del Carmen MG, Eisenhauer EL, Growdon WB, Goodman A, Dorney K, Mazina V, Sisodia RC.
- Gynecol Oncol. 2021 Dec 22:S0090-8258(21)01674-7. doi: 10.1016/j.ygyno.2021.12.017. Epub ahead of print.
- Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
- Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y, Qi X.
- Front Pharmacol. 2021 Dec 6;12:770663. doi: 10.3389/fphar.2021.770663.